Acción CMPX COMPASS THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Compass Therapeutics, Inc.

Acciones

CMPX

US20454B1044

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 21:51:22 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1,14 USD -5,00 % Gráfico intradía de Compass Therapeutics, Inc. +4,09 % -26,60 %
28/05 Compass Therapeutics, Inc. Anuncia cambios en su Consejo de Administración CI
28/05 Compass Therapeutics, Inc. anuncia cambios en la dirección CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics : 2024 Proxy Supplemental
Compass Therapeutics Appoints Thomas Schuetz as CEO
Compass Therapeutics Announces CEO Transition
Compass Therapeutics, Inc. Announces CEO Changes
Compass Therapeutics, Inc. Announces Management Changes
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Premarket Gainers
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics : 2024 Proxy
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CMPX
  4. Noticias Compass Therapeutics, Inc.
  5. Otros idiomas